Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538596 | 0.79 | LMNA (0.40) | HPGDALDH1A1LMNAL3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6926708 | 0.78 | LMNA (0.40) | HPGDALDH1A1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL4590444 | 0.72 | SIGMAR1 (0.42) | LMNASMN1; SMN2KMT2AMAPT | |
| SCHEMBL447843 | 0.70 | LMNA (0.55) | LMNAL3MBTL1SMN1; SMN2KMT2APOLB | |
| SCHEMBL10002496 | 0.68 | LMNA (0.53) | ALDH1A1LMNAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL4566294 | 0.67 | ALDH1A1 (0.40) | HPGDALDH1A1L3MBTL1SMN1; SMN2ALOX15 | |
| Acetamide SCHEMBL28420284 | 0.67 | HTT (0.43) | ALDH1A1LMNAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL30683848 | 0.67 | L3MBTL1 (0.54) | ALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL7457587 | 0.67 | L3MBTL1 (0.54) | ALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL6470509 | 0.66 | SLC6A9 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | HPGD 2413/4885ALDH1A1 4034/4885LMNA 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.